Chapter 823 Three circuit breakers in one day, 16.7 billion US dollars! The living devil of the pharmaceutical industry?
In mid-July, the national college entrance examination application process gradually came to an end.
Suddenly, a piece of news broke out, causing an uproar across the entire internet!
According to The Paper, a student in Zhoulai City who scored 683 points in the science section of the college entrance examination listed Senlian University as his first choice.
Although his score of 683 did not place him among the top scorers in the province, he was undoubtedly the top science student in the prefecture and city.
What level is Kesenlian University?
It's just a private, third-tier university.
Its only highlight is that it is backed by Senlian Group and has capitalized on the popularity of honorary principal Chen Yansen.
Prior to this, it ranked only 49th among universities in Huian Province, while there are a total of 50 undergraduate institutions in Huian Province, so its educational quality is self-evident.
It's worth noting that the admission score for a third-tier science college back then was only 483.
In other words, this candidate named Sun Chengwei, who clearly had the score to get into Tsinghua or Peking University, ultimately gave up top universities and chose Senlian University instead.
The news caused an uproar among netizens, with discussions erupting everywhere.
"Has this kid lost his mind? Why would he forgo a top university and go to a private, third-tier college?"
"Putting everything else aside, his school principal and teachers must be furious; their bonuses and performance bonuses are all gone!"
"How could my parents agree? If it were my child, they would give him a good beating. It's outrageous!"
The public opinion field is divided into two distinct camps.
Supporters believe Sun Chengwei is smart: if he went to Tsinghua or Peking University, he would most likely just be an ordinary member among many outstanding students; but if he joined Senlian, he would be the top student in the entire school.
As the saying goes, "It's better to be the head of a chicken than the tail of a phoenix." Standing out from the crowd makes it easier to gain opportunities for promotion and training.
Opponents bluntly stated that choosing a private school over a prestigious university is foolish for both children and parents.
The incident quickly escalated, with major portal websites and short video platforms reposting and reporting on it, making it a hot topic of discussion among the public.
Upon learning the news, Chen Yansen smiled faintly, offered a simple compliment, and then instructed Xiong Li to release the "Qingyun Plan Campus Version" policy.
The core message is clear: the top 100 students in each province's college entrance examination can enjoy a series of generous benefits as long as they apply to Senlian University.
Tuition and accommodation fees are waived, and a monthly living allowance of 2,000 yuan is provided.
Students can receive targeted training from Nobel laureates and winners of the Senlian Science and Technology Award;
Facilities such as the school's coffee shop, cinema, and drone club are all available for free use.
Of course, the benefits are not without requirements; candidates need to maintain a stable learning attitude and academic output.
After graduation, students will have priority to work in subsidiaries or core R&D laboratories of the Senlian Group.
The release of the detailed rules has once again caused a stir across the internet!
Let alone private universities, even public universities rarely offer such benefits.
"Free education, Nobel laureates as mentors, and guaranteed job placement after graduation"—Orange Education is clearly aiming to compete with top universities in China for students!
However, most parents still cling to the prestige of 211 and 985 universities and remain skeptical of Senlian University.
This deep-rooted obsession with prestigious universities is not hard to understand.
After capitalizing on the hype, Orange Education did not continue its extensive advertising. Instead, it quietly expanded its operations, accelerating the acquisition of kindergartens, primary and secondary schools, private universities, and vocational colleges across the country.
Enrollment slots will be prioritized for the children of employees within the Senlian Group, with only the remaining slots open to the general public.
...
...
On July 20, an even more significant piece of news emerged, completely overshadowing the public discussion surrounding college application.
The first report of BrainShield's Phase 1 clinical trial in North America has been officially released!
According to the trial data, among the 100 patients with mild, moderate and severe Alzheimer's disease included in the trial, the experimental group that received BrainShield drug treatment showed an average improvement of 62.7% in cognitive function scores after three months of continuous monitoring, and significantly enhanced activity of hippocampal neurons, without any serious adverse reactions.
In contrast, the control group receiving conventional drug treatment saw only a 2.2% improvement in cognitive function scores, with some patients experiencing a slow progression of their condition or even deterioration.
This is the most significant breakthrough in the treatment of Alzheimer's disease in nearly thirty years!
No one expected that the active ingredients extracted from Super Rice 2000 could be used to develop drugs that repair brain nerve cells.
It is important to know that, in the past, medical understanding held that once the brain nerve cells in the cerebral cortex were damaged, repair was almost impossible, and the process was irreversible.
After the BrainShield clinical trial report was released through Senlian Group's official channels, it instantly caused a huge stir in the global medical, academic, and capital markets.
That afternoon, the editorial departments of top international journals such as Nature and The Lancet contacted Orange Medical, urgently requesting complete trial data. Special issues originally scheduled for six months later were given priority for this report.
Several top pharmaceutical companies in North America and Europe held emergency meetings overnight, which immediately caused a stir in the capital market.
The stock prices of companies that have been investing in the research and development of Alzheimer's disease drugs for many years have fallen by more than 10% in a single day.
While Orange Medical, a subsidiary of Senlian Group responsible for the development of BrainShield, is not listed, the stock price of its holding company, Baichen Pharmaceuticals, has soared again, breaking through the US$15 billion market value mark.
This pharmaceutical company was acquired by Chen Yansen at the end of last year when he attended the Davos Economic Forum. In just six months, without launching any new drugs, its market value increased by 5 billion US dollars out of thin air.
Ultimately, top-notch scientific research achievements are like a gold mine.
The size of this gold mine is determined by the number of Alzheimer's patients worldwide!
With over 70 million patients worldwide, it's easy to imagine the staggering economic benefits NeuroGuard will generate once it's launched.
On social media, topics such as "Alzheimer's disease can be cured" and "the hidden skills of super rice" quickly topped the trending searches, with related discussions exceeding 100 million in just three hours.
Countless families with Alzheimer's patients left messages on the official WeChat account of Senlian Group and Chen Yansen's personal account, inquiring about the drug's launch date and clinical trial application process.
For these ordinary families, the pressure of caring for Alzheimer's patients is already overwhelming.
It's not that I'm unfilial or disregard family ties; it's just that life is inherently difficult.
Caring for a patient means that one of them must take time off work, as everything from food and groceries to medical expenses requires money.
A patient's ability to live independently directly determines the survival status of a family.
...
...
In the Senlian Science and Technology Park, Chen Yansen leaned back on the sofa in front of the floor-to-ceiling window, scrolling through the constantly refreshing messages on his phone screen.
These words contain so much of the hardship of ordinary families.
Some people recounted how the couple had taken turns taking time off work to care for their sick elderly relative over the past three years, and their savings had long been exhausted.
Some people admitted that they had just turned thirty when they were forced to resign to take care of their sick father, and the whole family relied on their wives' meager wages to make ends meet.
Some people expressed their helplessness, saying that their patients had gone missing twice before, and each time they were found, it was like going through a terrible ordeal.
Chen Yansen looked through the screenshots of daily life sent by netizens, sighed softly, and then notified Song Yongping: when the second phase of clinical trials begins, release more slots to the public.
Song Yongping is extremely efficient. That same afternoon, he adjusted the allocation plan for the Phase II clinical trial slots, updated the quota limit for the application channel on the official website, and added a special "Application Portal for Families in Difficulty," along with a simplified list of application materials and a QR code for online consultation.
As for the pricing of the Brain Shield, Chen Yansen is still considering it.
Pricing that is too low will hinder subsequent drug development and the planting and promotion of Super Rice 2000.
Excessive pricing will increase the financial burden on patients' families, which in turn will affect the compensation and bonuses of Orange Healthcare employees.
More importantly, it will slow down the growth rate of humanitarian torches.
On the other side.
In after-hours trading, the stock price of Baichen Pharmaceuticals surged to $16.7 per share, a single-day increase of 28.3%, triggering the circuit breaker mechanism three times during the period, with a market value of $16.7 billion.
Wall Street traders, their eyes bloodshot, chug cup after cup of coffee, some even yelling at their desks, "This isn't medicine, it's a money-printing machine!"
At the same time.
At Pfizer's headquarters in London, CEO Albert woke up the global vice president of R&D overnight to hold an emergency video conference.
"Can any of you point out a single mistake in Orange Medical's trial data? Even just one!"
Albert questioned him sharply, but no one dared to answer.
It's worth noting that BrainShield's Phase I clinical trial is not yet complete, and Phase II trials have just begun, yet it has already completely outclassed Pfizer's Phase III candidate drug.
Once NeuroGuard is officially launched, Pfizer's nearly $7 billion investment in Alzheimer's drug development will be completely wasted.
At this moment, European and American pharmaceutical companies deeply felt the helplessness that the semiconductor industry had experienced six months ago.
Six months ago, they had no choice but to reluctantly bring Xingyuan Technology and Tiangong Technology to the negotiating table.
Right now, the pharmaceutical industry has also welcomed this living devil.
The emergence of BrainShield caused the stock prices of more than a dozen leading pharmaceutical companies to decline collectively.
The number of people who wanted Chen Yansen dead was increasing, but correspondingly, the number of people who saw him as their savior also reached an unprecedented scale.
However, not long after, negative public opinion against BrainShield began to emerge overseas.
An anonymous source posted so-called inside information on social media, claiming that the clinical trial data for Brain Shield was fabricated and that some patients experienced hidden nerve damage after taking the drug, which was deliberately concealed by Orange Medical.
Some media outlets have also jumped on the bandwagon, linking the development of BrainShield with topics such as "gene editing ethics" and "biosafety," attempting to smear Orange Medical's international image and hinder the global promotion of the new drug.
"Those bastards, from now on, prices in all these areas will increase by 50%!"
Chen Yansen gave the orders while cursing.
He remained completely calm in the face of negative public opinion.
Although Senlian Capital does not own print media, it owns several phenomenal apps such as Mimo, Xiaohongshu, and Lingxi Browser. It quickly used the report from the North American Pharmaceutical Regulatory Association to refute these media outlets that were fabricating stories.
Following that, both print and streaming media were added to the list of lawsuits filed by the legal department of Senlian Group.
(End of this chapter)
Continue read on readnovelmtl.com
